dc.contributor.author
Jeschke, Elke
dc.contributor.author
Searle, Julia
dc.contributor.author
Günster, Christian
dc.contributor.author
Baberg, Henning Thomas
dc.contributor.author
Dirschedl, Peter
dc.contributor.author
Levenson, Benny
dc.contributor.author
Malzahn, Jürgen
dc.contributor.author
Mansky, Thomas
dc.contributor.author
Möckel, Martin
dc.date.accessioned
2018-06-08T11:06:09Z
dc.date.available
2017-11-23T12:08:04.016Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/21613
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-24902
dc.description.abstract
Objectives To describe the use of drug-eluting stents (DESs) in the largest
population of statutory health insurance members in Germany, including newly
developed bio-resorbable vascular scaffolds (BVSs), and to evaluate 1-year
complication rates of DES as compared with bare metal stents (BMSs) in this
cohort. Design Routine data analysis of statutory health insurance claims data
from the years 2008 to 2014. Setting The German healthcare insurance
Allgemeine Ortskrankenkasse covers approximately 30% of the German population
and is the largest nationwide provider of statutory healthcare insurance in
Germany. Participants and interventions We included all patients with a claims
record for a percutaneous coronary intervention (PCI) with either DES or BMS
and additionally, from 2013, BVS. Patients with acute myocardial infarction
(AMI) were excluded. Main outcome measure: major adverse cerebrovascular and
cardiovascular event (MACCE, defined as mortality, AMI, stroke and transient
ischaemic attack), bypass surgery, PCI and coronary angiography) at 1 year
after the intervention. Results A total of 243 581 PCI cases were included
(DES excluding BVS: 143 765; BVS: 1440; BMS: 98 376). The 1-year MACCE rate
was 7.42% in the DES subgroup excluding BVS and 11.29% in the BMS subgroup.
The adjusted OR for MACCE was 0.72 (95% CI 0.70 to 0.75) in patients with DES
excluding BVS as compared with patients with BMS. In the BVS group, the
proportion of 1-year MACCE was 5.0%. Conclusion The analyses demonstrate a
lower MACCE rate for PCI with DES. BVSs are used in clinical routine in
selected cases and seem to provide a high degree of safety, but data are still
sparse.
de
dc.rights.uri
http://creativecommons.org/licenses/by-nc/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Drug-eluting stents in clinical routine
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
BMJ Open. - 7 (2017), 7, Artikel Nr. e017460
dc.title.subtitle
a 1-year follow-up analysis based on German health insurance administrative
data from 2008 to 2014
dcterms.bibliographicCitation.doi
10.1136/bmjopen-2017-017460
dcterms.bibliographicCitation.url
http://dx.doi.org/10.1136/bmjopen-2017-017460
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000028534
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000009154
dcterms.accessRights.openaire
open access